Recombinant human endostatin combined with chemotherapy in treatment of advanced malignant tumors.

Objective:To evaluate the efficacy and safety with the combination of rh-endostatin(endostar) and chemotherapy in patients with advanced malignant tumors.Methods:Twenty-nine patients with advanced cancers confirmed by histopathology or cytopathology were administrated with endostar 7.5mg/m2(day 1-14) by vein infusion of 3-4 hours and routine chemotherapy every 3 weeks.The overall response and toxicity were observed.Results:Twenty-nine patients were entered,28 patients were evaluable.Partial response was observed in 9 patients,stable disease in 12 patients and progressive disease in 7 patients.Overall response rate was 32.1%(9/28),clinical benefit rate was 75%(21/28).No serious adverse events were observed.Conclusion:The rh-endostatin combined with chemotherapy tends to show a better efficacy than chemotherapy alone and is well tolerated in advanced malignant tumors patients.No obviously adverse event was observed in these patients.